Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4825010 | 0.89 | DRD4 (0.48) | KDM4ELMNANPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4823578 | 0.86 | DRD4 (0.52) | KDM4ELMNASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL4817067 | 0.83 | KDM4E (0.52) | KDM4ELMNAALDH1A1TP53HTR1A | |
| SCHEMBL4825079 | 0.81 | PARP1 (0.42) | HTR2BHTR1ADRD4 | |
| SCHEMBL4818594 | 0.81 | DRD4 (0.51) | HTR1ADRD4DRD2 | |
| SCHEMBL4824115 | 0.80 | ALDH1A1 (0.57) | KDM4ELMNANPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4820489 | 0.80 | HTR2B (0.39) | HTR2BHTR1ADRD4DRD2 | |
| SCHEMBL4819167 | 0.79 | DRD4 (0.57) | KDM4EALDH1A1HTR1ADRD4MAPT | |
| SCHEMBL7106423 | 0.78 | HTR1A (0.48) | KDM4ELMNAALDH1A1TP53HTR1A | |
| SCHEMBL3605597 | 0.75 | SIGMAR1 (0.76) | KDM4ELMNANPSR1ALDH1A1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470691-B2 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2008-12-30 | — | — | US | claimed |
| US-20070265249-A1 | Fused Bicyclic Aromatic Compounds that are Useful in Treating Sexual Dysfunction | ABBVIE INC. | 2007-11-15 | — | — | US | claimed |
| US-20060172995-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBVIE INC. | 2006-08-03 | — | — | US | claimed |
| US-7057042-B2 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2006-06-06 | — | — | US | claimed |
| US-20040063713-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBVIE INC. | 2004-04-01 | — | — | US | claimed |
| US-20040002488-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | WEINSTOCK, STEVEN F. | 2004-01-01 | — | — | US | claimed |
| WO-2003101994-A1 | FUSED BICYCLIC AROMATIC COMPOUNDS THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-12-11 | — | — | WO | claimed |
| US-7470691-B2 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2008-12-30 | — | — | US | disclosed |
| US-20070265249-A1 | Fused Bicyclic Aromatic Compounds that are Useful in Treating Sexual Dysfunction | ABBVIE INC. | 2007-11-15 | — | — | US | disclosed |
| US-7235661-B2 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2007-06-26 | — | — | US | disclosed |
| US-20060172995-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBVIE INC. | 2006-08-03 | — | — | US | disclosed |
| US-7057042-B2 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2006-06-06 | — | — | US | disclosed |
| US-20040063713-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBVIE INC. | 2004-04-01 | — | — | US | disclosed |
| US-20040002488-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | WEINSTOCK, STEVEN F. | 2004-01-01 | — | — | US | disclosed |
| WO-2003101994-A1 | FUSED BICYCLIC AROMATIC COMPOUNDS THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063713-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | CYP19A1, CYP17A1, HSD17B11 | KDM4E 3657/4885LMNA 4670/4885NPSR1 532/4885 |
| US-20070265249-A1 | Fused Bicyclic Aromatic Compounds that are Useful in Treating Sexual Dysfunction | CYP19A1, CYP17A1, HSD17B11 | KDM4E 2778/4885LMNA 2277/4885NPSR1 640/4885 |
| US-20060172995-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | CYP19A1, CYP17A1, DDC | KDM4E 2026/4885LMNA 3391/4885NPSR1 675/4885 |
| US-20040002488-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | CYP19A1, CYP17A1, HSD17B11 | KDM4E 3657/4885LMNA 4670/4885NPSR1 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.